Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Post by JayjayUSA12007on Jun 18, 2019 9:51pm
150 Views
Post# 29838327

Thera just blew it !

Thera just blew it !
Just by reading its presentation, I have the impression that:
1/ They drafted in a hurry for some reasons without spending a lot of time on it. This is in contrast with Madrigal's presentation. Kind of having a feeling of amateurish !
2/ Definitely, Thera doesn't seem to have Dr Grinspoon's data. This explains the non-technical, shallow and superficial aspects of its presentation.

So, why the rush to announce something that obvious, since Thera just had a press release on 06/14 announcing positive results from Dr Grinspoon's trial ? There is no need to confirm the pursuit of Phase 3 trial on HIV patients with a CC, since it's a given, unless you have something else such as label expansion in the interim. A detail PR with market analysis would suffice. It seems to me Thera was trying to please someone, or some "tutes", for perhaps they have been in talk about something. Just my guess.
Bullboard Posts